Natixis Clovis Oncology, Inc. Transaction History

Natixis

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $525,000 - $1.43 Million	500,000 New	500,000 $600,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $135,000 - $238,000	-50,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$4.06 - $5.8 $246,441 - $352,060	-60,700 Reduced 54.83%	50,000 $223,000
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $555,714 - $780,435	110,700 New	110,700 $642,000
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $97,142 - $208,826	-20,196 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$4.13 - $6.41 $4.42 Million - $6.85 Million	-1,069,240 Reduced 98.15%	20,196 $97,000
Q3 2020 Nov 12, 2020	BUY	$4.82 - $7.72 $5.25 Million - $8.41 Million	1,089,436 New	1,089,436 $6.35 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $313,725 - $465,441	-7,459 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $373,845 - $505,123	7,459 New	7,459 $394,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $197,645 - $289,771	-3,426 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $230,124 - $290,559	3,426	3,426 $282,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.